Merck (MRK) Stock: Heart Drug Trial Results Push Shares Up

TLDR

• Merck shares surged 8.5% after Phase 3 trial results showed enlicitide decanoate effectively lowered LDL cholesterol with minimal side effects
• The once-daily oral medication demonstrated high patient compliance and safety comparable to placebo in treating familial hypercholesterolemia
• Third quarter earnings exceeded forecasts at $2.58 per share with revenues of $17.3 billion and improved full-year guidance
• European regulators approved KEYTRUDA as monotherapy for head and neck cancer, expanding treatment options across new markets
• A $700 million partnership with Blackstone Life Sciences will fund development of sacituzumab tirumotecan for multiple cancer applications

Merck stock jumped 8.5% following the release of Phase 3 clinical data for enlicitide decanoate. The experimental oral medication targets LDL cholesterol reduction in cardiovascular disease patients.

Merck & Co., Inc., MRK

The company presented findings at the American Heart Association Scientific Sessions 2025. Results showed the once-daily PCSK9 inhibitor produced sustained LDL cholesterol reductions in patients with familial hypercholesterolemia and high-risk adults.

The trial highlighted strong patient adherence throughout the study period. Safety data matched placebo levels, addressing a critical consideration for cardiovascular treatments.

Enlicitide decanoate offers an oral alternative to existing injectable PCSK9 inhibitors. This delivery method could improve patient compliance compared to current injection-based options in the cholesterol management market.

Quarterly Results Exceed Analyst Projections

Merck reported adjusted third quarter earnings of $2.58 per share, beating Wall Street estimates. Total quarterly revenues reached $17.3 billion, reflecting continued growth across therapeutic areas.

The company maintains a 35.4% EBIT margin while investing heavily in research programs. Management raised full-year 2025 guidance following the quarterly performance.

With an enterprise value near $238 billion, Merck shows financial strength. The current ratio of 1.7 indicates healthy liquidity for ongoing operations and development programs.

Revenue projections target $72 billion by 2028, requiring 4.2% annual growth. Earnings forecasts call for reaching $24.3 billion, up from the current $16.4 billion baseline.

Cancer Treatment Portfolio Expands

The European Commission granted approval for KEYTRUDA as standalone therapy for head and neck cancer. This regulatory decision opens additional European markets for Merck’s leading oncology product.

Clinical data showed KEYTRUDA combined with WELIREG demonstrated effectiveness treating clear cell renal carcinoma following surgical intervention. The combination approach extends treatment applications in kidney cancer.

KEYTRUDA continues as the primary revenue generator in Merck’s oncology division. Sales from this immunotherapy drug support overall company growth targets.

Merck finalized a $700 million funding agreement with Blackstone Life Sciences. The capital will accelerate clinical development of sacituzumab tirumotecan across various cancer types.

The partnership strengthens Merck’s oncology pipeline beyond KEYTRUDA. Sacituzumab tirumotecan shows potential applications in multiple tumor classifications pending successful trial outcomes.

Stock analysts value Merck shares between $74.77 and $228.66 per share. The valuation range reflects varying assumptions about new product launch timing and market penetration.

Tuesday trading saw the stock up 2.39% in early sessions. Investor response remained positive to both cardiovascular and cancer treatment developments announced by the company.

The enlicitide decanoate data positions Merck in the competitive cholesterol treatment sector. Clinical success with this oral formulation could capture market share from existing injectable therapies.

The post Merck (MRK) Stock: Heart Drug Trial Results Push Shares Up appeared first on Blockonomi.